Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus neoadjuvant chemotherapy and adjuvant endocrine therapy versus placebo in high-risk ER-positive/HER2-negative primary breast cancer
CTR20210054Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in breast cancer, sponsored by Bristol Myers Squibb. Started Jun 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20210054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210054.